Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04377672 · ClinicalTrials.gov registry record · Phase 1
Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)
A Phase 1 study of SARS CoV 2 Infection, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT04377672: Completed Phase 1 study of SARS CoV 2 Infection, sponsored by Johns Hopkins University.
NCT04377672 is a Phase 1 study of SARS CoV 2 Infection that has completed, run by Johns Hopkins University. The registered enrollment target is 14 participants, below the 4,187-participant average among 35 other SARS CoV 2 Infection trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04377672, a Phase 1 study of SARS CoV 2 Infection, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety of administration of plasma containing antibodies to the SARS-CoV-2 virus (i.e., convalescent plasma) and if it is able to prevent disease or lessen the severity of disease in individuals who are at high risk of developing COVID-19 due to a recent exposure. This study will also measure the level of anti-SARS-CoV-2 antibodies in patient's blood after the administration of the convalescent plasma.
Primary Outcome
Number of subjects with grade 3 and 4 adverse events during the study period.
Conditions Studied
Interventions
- BIOLOGICAL Anti-SARS-CoV-2 Human Convalescent Plasma
Study Locations (1)
Maryland
- Johns Hopkins Hospitals - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-05-28 |
| Est. Completion | 2021-12-13 |
| Phase | Phase 1 |
What the finished NCT04377672 record still lists
NCT04377672 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 4,187-participant average among 35 other SARS CoV 2 Infection trials with a reported enrollment target (100% lower).
The record links to 1 condition, with SARS CoV 2 Infection appearing as the primary indexed condition, and to 1 intervention - of which Anti-SARS-CoV-2 Human Convalescent Plasma is the first listed.
NCT04377672 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04377672 about?
NCT04377672 is a clinical study titled "Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)". The purpose of this study is to evaluate the safety of administration of plasma containing antibodies to the SARS-CoV-2 virus (i.e., convalescent plasma) and if it is able to prevent disease or lessen the severity of disease in individuals who are at high risk of developing COVID-19 due to a recent ...
What is the current status of trial NCT04377672?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2020-05-28. Estimated completion is 2021-12-13.
What conditions does trial NCT04377672 study?
This clinical trial studies the following conditions: SARS CoV 2 Infection.
What interventions are being tested in trial NCT04377672?
The interventions under investigation include: Anti-SARS-CoV-2 Human Convalescent Plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04377672?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04377672 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS CoV 2 Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04377672's enrollment target sits among peer trials
14 36th of 35 the lowest of 35 other SARS CoV 2 Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other SARS CoV 2 Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients
RECRUITING · Phase 1
-
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
RECRUITING · Phase 1
-
Pancoronavirus Vaccine Study in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Exercise in Child Health
RECRUITING · NA
-
NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19
RECRUITING
-
Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy